OR WAIT null SECS
Austin, TX-November 18, 2009
Rules-Based Medicine, Inc. (RBM) has entered into a biomarker alliance and services agreement with Covance Inc. The alliance is intended to provide biotechnology and pharmaceutical companies with a combination of biomarker technologies and services for use in drug development.
Under terms of the agreement, Covance will use RBM as its exclusive third-party provider of multiplexed protein biomarker testing services, and RBM shall use Covance as its exclusive referral source for laboratory testing services. Financial terms of the agreement have not been disclosed.
“Biomarkers can be critical in the effort to bring new medicines to market,” said Craig Benson, RBM president and chief executive officer. “We believe this alliance can provide RBM with greater access to drug developers seeking to implement biomarker strategies in order to improve the effectiveness of their clinical trials. We are pleased to link our efforts to those of Covance, a world-class drug development services company.”